Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease
(Source: CEN Case Reports)
Source: CEN Case Reports - January 22, 2016 Category: Urology & Nephrology Source Type: research
Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study
Conclusion: In this study, patients with solid tumors receiving DA per European indication for symptomatic chemotherapy-induced anemia had clinically meaningful improvements in Hb and QoL.Keyword: darbepoetin alfa, erythropoiesis-stimulating agent, fatigue visual analog scale, Functional Assessment of Cancer Therapy-Fatigue subscale, transfusion (Source: Cancer Management and Research)
Source: Cancer Management and Research - January 20, 2016 Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Effectiveness of Darbepoetin Alfa for Chemotherapy-Induced Anemia When Initiated at Hemoglobin ≤10 g/dL.
Abstract
PURPOSE: Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when initiated at Hb ≤10 g/dL (the threshold specified in the summary of prescribing characteristics). We assessed DA, initiated according to current labeling (Hb ≤10 g/dL), in chemotherapy-induced anemia (CIA).
METHODS: Data for patients with cancer and CIA who initiated DA at Hb ≤10 g/dL were extracted from a database of Amgen-sponsored trials. A comparative analysis was limited to randomized, controlled trials in patients treated with DA ...
Source: Clinical Therapeutics - December 22, 2015 Category: Drugs & Pharmacology Authors: Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey JH Tags: Clin Ther Source Type: research
Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy
Conclusions: Erythropoietin-stimulating agents were effective in reducing blood transfusion need. Granulocyte colony-stimulating factors were effective in lowering neutropenia incidence and also were associated with improved survival in elderly ovarian cancer patients. Findings are consistent with clinical trials and clinical guidelines. (Source: International Journal of Gynecological Cancer)
Source: International Journal of Gynecological Cancer - December 15, 2015 Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
Reduction of costs for anemia-management drugs associated with the use of ferric citrate.
CONCLUSION: It is likely that US health care costs for anemia-management drugs associated with ESRD among HD patients can be reduced by using ferric citrate as a phosphate binder.
PMID: 24899820 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - November 28, 2015 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability.
CONCLUSION: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses.
PMID: 25336984 [PubMed] (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - November 28, 2015 Category: Urology & Nephrology Tags: Int J Nephrol Renovasc Dis Source Type: research
Cloning and expression of codon-optimized recombinant darbepoetin alfa in Leishmania tarentolae T7-TR
This study desribes the secretory expression of a codon-optimized recombinant form of darbepoetin alfa in Leishmania tarentolae T7-TR. Synthetic codon-optimized gene was amplified by PCR and cloned into the pLEXSY-I-blecherry3 vector. The resultant expression vector, pLEXSYDarbo, was purified, digested, and electroporated into the L. tarentolae. Expression of recombinant darbepoetin alfa was evaluated by ELISA, reverse-transcription PCR (RT-PCR), Western blotting, and biological activity. After codon optimization, codon adaptation index (CAI) of the gene raised from 0.50 to 0.99 and its GC% content changed from 56% to 58%....
Source: Protein Expression and Purification - November 3, 2015 Category: Molecular Biology Source Type: research
Efficiency of erythropoiesis-stimulating agents (ESA) in the treatment of chemotherapy-induced anemia in patients with lung cancer (LC)
In this study epoetin alfa was better in terms of efficiency than epoetin beta and darbepoetin. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Tiotiu, A., Clerc-Urmes, I., Martinet, Y. Tags: 11.1 Lung Cancer Source Type: research
Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients
Conclusions
The study results suggest that TSAT is the best predictor of the initial 12-week responsiveness to ESA, irrespective of the type. Variables not investigated in this study also affect responsiveness to ESA in Japanese pre-dialysis CKD patients. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - October 28, 2015 Category: Urology & Nephrology Source Type: research
Acute onset anterior uveitis after darbepoetin alfa infusion
Abstract
A 79-year-old female with a 2-month history of newly diagnosed myelodysplastic syndrome for which she received blood transfusion with darbepoetin alfa presented with bilateral anterior uveitis 1 day after her fourth transfusion. On exam, visual acuity was 20/20 in both eyes with biomicroscopy notable for conjunctival injection and anterior chamber cell and flare consistent with anterior uveitis. She had no systemic symptoms, no history of eye trauma, and no known infections. This case, along with prior reports in the literature, suggests that anterior uveitis may be an idiosyncratic complicati...
Source: Journal of Ophthalmic Inflammation and Infection - October 26, 2015 Category: Opthalmology Source Type: research
Economic Evaluation of The Aranesp Application for Anemia Correction In Pathients With Chronical Renal Failure on Hemodialysis or Peritoneal Dialysis In Russia
to assess the cost effectiveness of the application of darbepoetin alfa vs other erythropoiesis-stimulating agents for anemia correction in patients on hemodialysis or peritoneal dialysis. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: TS Fakeeva, I Krysanov Source Type: research
Treatment of renal anemia with erythropoiesis‐stimulating agents in predialysis chronic kidney disease patients: Hemoglobin profile during the 6 months before initiation of dialysis
ConclusionLong‐acting ESAs may be more useful for predialysis patients with CKD because they do not attend hospital frequently, unlike hemodialysis patients. This article is protected by copyright. All rights reserved. (Source: Nephrology)
Source: Nephrology - October 12, 2015 Category: Urology & Nephrology Authors: Kazuhiko Kawahara, Jun Minakuchi, Narushi Yokota, Hiroto Suekane, Kenji Tsuchida, Shu Kawashima Tags: Supplement Article Source Type: research
Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity‐matched analysis
ConclusionOur study showed that C.E.R.A. may be more effective than DA for management of anemia during the predialysis period in CKD patients. This article is protected by copyright. All rights reserved. (Source: Nephrology)
Source: Nephrology - October 11, 2015 Category: Urology & Nephrology Authors: Kiyoto Koibuchi, Moriatsu Miyagi, Taichi Arai, Toshiyuki Aoki, Atsushi Aikawa, Ken Sakai Tags: Supplement Article Source Type: research
Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease
ConclusionThe placebo‐controlled cohort of heart failure patients with anaemia, diabetes mellitus, and chronic kidney disease from RED‐HF provides confirmation of the increased stroke risk associated with DA use identified in TREAT. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - October 1, 2015 Category: Cardiology Authors: Natalie A. Bello, Eldrin F. Lewis, Akshay S. Desai, Inder S. Anand, Henry Krum, John J.V. McMurray, Kurt Olson, Scott D. Solomon, Karl Swedberg, Dirk J. van Veldhuisen, James B. Young, Marc A. Pfeffer Tags: Original Article Source Type: research
How the Target Hemoglobin of Renal Anemia Should Be
Renal anemia is caused by the deficiency of endogenous erythropoietin (Epo) due to renal dysfunction. We think that it is possible to slow the progression of chronic kidney disease (CKD) in case we initiate Epo early in pre-dialysis patients, especially in the non-diabetic population. Erythropoiesis stimulating agent (ESA) treatments targeting mild anemia (10-12 g/dl) can decrease the risk of occurrence of cardiovascular disease (CVD) in patients with hypertension, diabetes mellitus and congestive heart failure. As the large randomized controlled trials such as Cardiovascular Risk Reduction by Early Anemia Treatment with E...
Source: Nephron - September 22, 2015 Category: Urology & Nephrology Source Type: research
